Allurion and Medtronic inked a sales agency agreement in the Central and Eastern Europe, Middle East, and Africa (CEMA) region. The agreement aims to expand access to Allurion’s artificial intelligence-powered weight loss program. It enables Allurion to offer its Allurion Balloon and accelerate the utilization of its Iris AI platform. The company aims to leverage Medtronic’s channels to enhance the management of bariatric surgery patients.
Natick, Massachusetts-based Allurion’s program combines its Allurion Balloon with the Allurion Virtual Care Suite. The company said its balloon is the world’s first and only swallowable, procedure-less gastric balloon for weight loss. Its Iris platform powers the Virtual Care Suite, a remote patient monitoring solution. The company also offers the Virtual Care Suite as a standalone product.
“We are thrilled to join forces with Medtronic to expand access to our weight loss program. Medtronic has exceptional distribution capabilities across a number of different channels that can augment our base business,” said Dr. Shantanu Gaur, Allurion’s founder and CEO. “We also believe this partnership will help accelerate adoption of our Iris AI Platform as a standalone offering to streamline the management of patients undergoing bariatric surgery and potentially improve outcomes, further cementing our position as a leader in AI and weight management.”
Allurion announced its intention to go public through a business combination with Compute Health in February 2023. Medtronic is currently an investor in Compute Health, a special purpose acquisition corporation (SPAC). This agreement builds upon their existing relationship. Former Medtronic CEO Omar Ishrak serves as chair of the SPAC’s board of directors.
